Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
crnx · stock forecast · 18 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 18 Wall Street analysts in the past 3 months
Buy
18 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$105
Consensus
$85.83
+156.4% upside
Low
$67.00
Median: $85.5 · Last Close: $33.48
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$85.83
156.4% upside
High Target
$105
213.6%
Low Target
$67
100.1%
Current Price
$33.48
as of today
Based on analyst price targets, the CRNX stock price prediction for the next 12 months ranges from $67 to $105. The consensus CRNX price forecast of $85.83 implies 156.4% upside from the current price of $33.48.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $32.01 | ↓ 4.38% |
1-day model range: $31.79–$32.24. Peak: $32.24 (-4.38%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $36 | +6.7% |
| 2028 | $37 | +11.0% |
| 2029 | $38 | +13.7% |
| 2030 | $39 | +15.4% |
| 2031 | — | +16.4% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRNX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-05-11 | Oppenheimer | Maintains | Outperform→Outperform |
| 2026-05-08 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-04-28 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-03-02 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-01-12 | Goldman Sachs | Upgrade ↑ | Neutral→Buy |
| 2026-01-08 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-01-06 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2025-11-07 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2025-09-30 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Crinetics Pharmaceuticals, Inc. (CRNX) stock. Of the recent 80 rating actions, 3 were upgrades and 0 were downgrades. 18 analysts currently cover CRNX.
Analyst Recommendation Trends
CRNX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 6 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$69M
↓ 83.7% YoY
Revenue Next Year
$173M
↑ 152.4% YoY
EPS This Year
$-4.80
EPS Next Year
$-4.21
↓ 12.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRNX EPS of $-4.80 for the current fiscal year, based on estimates from 10 analysts. The CRNX revenue forecast is $69M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CRNX stock forecast is supported by two independent data sources: analyst consensus ratings from 18 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRNX price target is $85.83 (+156.4% upside), with an analyst consensus of Buy.
The CRNX short-term stock prediction for tomorrow is $32.01 (-4.38%). The CRNX stock price prediction for 2027 estimates an average of $36. The CRNX stock prediction for 2030 projects a range of $36–$42.
Crinetics Pharmaceuticals, Inc. trades on NASDAQ under the ticker CRNX. The CRNX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
CRNX forecast · 8 questionsAccording to 18 Wall Street analysts, the average 12-month CRNX price target is $85.83, with a high forecast of $105.00 and a low of $67.00. The median price target is shown in the chart above when available. This implies +156.4% potential upside from the current price of $33.48.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.